Breast Cancer
Red Flags — criteria for a suspected cancer pathway referral and urgent action
| Red flag | Why significant | Action |
|---|---|---|
| Unexplained breast lump in patient aged ≥30 years | NICE NG12: this is the primary suspected cancer pathway referral criterion. "Unexplained" = lump that cannot be confidently attributed to a benign cause on clinical examination alone. At age 47 with a 6-week painless lump: the clinical examination alone is insufficient to exclude cancer. Triple assessment is required. Do not reassure without suspected cancer pathway referral. | Suspected cancer pathway referral (NG12) |
| Skin changes suggesting breast cancer (any age) | Skin puckering, dimpling (traction by Cooper's ligaments); peau d'orange (lymphoedema of dermis from dermal lymphatic blockage); skin nodule over breast; erythema (inflammatory breast cancer). These may represent locally advanced disease. NG12 1.4.2: consider a suspected cancer pathway referral for skin changes suggesting breast cancer, at any age. | Suspected cancer pathway referral (any age); peau d'orange: may require same-day assessment |
| Nipple changes in patient aged ≥50 years | NICE NG12 (updated April 2026) 1.4.1: aged ≥50 with discharge, retraction or other changes of concern in one nipple only = suspected cancer pathway referral. Examples: new unilateral nipple retraction (suspicious for subareolar malignancy pulling the nipple inward); unilateral bloodstained or serosanguinous discharge. Under 50, nipple symptoms are not an NG12 criterion — assess and refer if clinically concerned (e.g. discharge with a lump). | Suspected cancer pathway referral (≥50 years with nipple changes); bloodstained discharge under 50: refer on clinical judgement (not an NG12 criterion) |
| Unexplained lump in axilla aged ≥30 years | Axillary lymph node enlargement in breast cancer context: highly significant. Isolated hard axillary lymphadenopathy in a woman ≥30 may represent nodal spread of occult breast primary (occult primary is rare but important). Also: lymphoma (bilateral, soft, mobile); reactive (recent infection). Clinical examination of both breast and axilla in every woman presenting with axillary lump. | Suspected cancer pathway referral; examine breast; USS axilla; if bilateral lymphadenopathy: consider lymphoma pathway |
| Suspected inflammatory breast cancer | Inflammatory breast cancer: rapid onset breast swelling, erythema, warmth, peau d'orange; may not have a discrete lump; often mistaken for mastitis; accounts for approximately 1–5% of breast cancers but is aggressive with poorer prognosis. Key discriminator from mastitis: inflammatory BC does not respond to antibiotics; recurrence after antibiotics; no fever/systemic illness. Any apparent "mastitis" in a non-breastfeeding woman ≥30 that does not resolve with a course of antibiotics: urgent suspected cancer pathway referral. | Urgent breast assessment if atypical or not improving promptly with appropriate treatment — not an NG12 criterion; do not diagnose inflammatory BC in primary care or issue repeated antibiotic courses |
| Signs of metastatic disease (bone pain, cough, weight loss, neurological symptoms) | Metastatic breast cancer presents at diagnosis in 5–10% of cases. Bone metastases (most common): persistent bone pain; pathological fracture; hypercalcaemia. Lung: cough, dyspnoea. Liver: jaundice, RUQ pain, abnormal LFTs. Brain: headache, focal neurology. If breast lump is accompanied by unexplained weight loss, persistent bone pain, or neurological symptoms: priority suspected cancer pathway referral or direct admission depending on severity. | Priority suspected cancer pathway referral; bloods (LFTs, calcium, FBC, LDH); bone X-ray if pain; chest X-ray; CT if metastatic disease suspected |
Safeguarding Considerations in Breast Cancer Presentation
🚨 Delayed Presentation — Domestic Abuse or Control
- Delayed presentation (6 weeks in Sarah's case) may reflect fear, avoidance, or inability to seek care without a partner's permission
- In abusive relationships: access to healthcare may be controlled or discouraged; health problems may be minimised or dismissed by an abusive partner
- Sarah coming without her husband and not having told him: may be appropriate privacy — but screen sensitively for coercive control
- Ask about domestic abuse sensitively and in private — a new serious diagnosis is a moment of increased vulnerability
💊 Non-Disclosure and Self-Harm Risk at Diagnosis
- Breast cancer diagnosis carries significant psychological burden; risk of depression, anxiety, and in a minority of cases, suicidal ideation
- Patients who have not told family (like Sarah) may feel isolated with a potentially devastating diagnosis
- PHQ-9 or brief wellbeing screen at the suspected cancer pathway result appointment; ensure support network is in place
- Cancer charity helplines: Breast Cancer Now (number on their website); Macmillan (number on their website)
🧒 Children in the Household
- Sarah has a 19-year-old child — likely independent but may be at home
- Younger children in household of a breast cancer patient: safeguarding consideration if parent's health deteriorates and childcare is affected
- Younger patients (under 50) with young children: additional psychosocial complexity; childcare arrangements if chemotherapy/surgery required
- Practical support: social worker input; Macmillan practical support
🔬 Fertility Preservation
- Women under 50 facing chemotherapy: fertility may be affected (cyclophosphamide and other alkylating agents suppress ovarian function)
- NICE NG257 (March 2026; replaced CG156): discuss the effect of cancer treatment on fertility at diagnosis and offer oocyte or embryo cryopreservation before treatment likely to cause infertility; refer early to fertility services
- Sarah: 47, pre-menopausal; if chemotherapy likely, fertility discussion required even if family is complete (premature menopause from chemotherapy)
- HER2+ disease in younger women: trastuzumab during pregnancy is contraindicated; contraception planning required
😰 Fear and Avoidance
Six weeks of anxiety is clinically significant. The GP who treats this as purely a clinical presentation misses an opportunity to address the underlying fear, which will affect adherence to the referral pathway. Patients who are extremely frightened sometimes avoid follow-up appointments, decline biopsy, or delay treatment — all of which worsen outcomes. Addressing the fear explicitly — validating it while providing a clear plan — is therapeutic and clinically important.
"Finding something like this and sitting with it for six weeks — that takes real courage. I want to tell you something: you have done exactly the right thing by coming in now. The time you have waited has not cost you anything in terms of your care — and we are going to get to the bottom of this properly."👥 The Friend with Breast Cancer
Sarah's friend's breast cancer experience is central to her psychological state. She has watched someone she cares about go through diagnosis, surgery, chemotherapy, and all that entails. This experience both motivated her to seek review (eventually) and amplified her fear. A gentle enquiry — "tell me about your friend's experience" — surfaces what Sarah knows, fears, and has projected onto her own situation. It also allows the GP to acknowledge that cancer experiences differ significantly: not all breast cancer is the same stage, the same treatment, or the same outcome.
"You mentioned your friend had breast cancer. It sounds like watching that was really difficult. I want you to know that every person's situation is different — the experience your friend had tells you that this happens, not that this is what is going to happen to you. Whatever we find, we face it with information, not with what happened to someone else."🤫 Not Telling the Family
Sarah has not told her husband or family. This is a significant psychological burden — carrying a secret that feels potentially life-altering. The GP should not pressure her to disclose prematurely, but should gently explore why she has not told anyone and whether she has someone to support her. Going to a breast clinic appointment alone, if a biopsy or difficult news is possible, is a significant additional stress. "Is there anyone who could come with you?" is an important practical question that is also an offer of support.
"You mentioned you haven't told your husband yet. I completely understand why — you didn't want to worry anyone until you knew something for certain. But you are going to have a clinic appointment in the next week or two, and it might help to have someone with you. You don't have to tell them everything right now — but is there anyone you trust who could go with you?"🏫 Occupational Impact
Sarah is a secondary school teacher. Term-time pressures may have contributed to her delay in seeking review. If a significant diagnosis follows, there will be practical questions about sick leave, disclosure to the school, and managing a class while undergoing treatment. Teaching is a demanding physical and emotional role; chemotherapy side effects (fatigue, infection risk) and surgery have direct occupational implications. Early social work or occupational health involvement, if a diagnosis follows, is important. For now: acknowledge that timing this in term time is additionally stressful.
"I know you're a teacher — the timing of all of this, in term time, adds extra pressure. Whatever the results show, there is support available to help you manage your work alongside any treatment. You should not feel you have to manage this alone or that your job takes priority over your health."🔬 OCP and Risk Perception
Sarah is on the combined OCP. In the context of a potential breast cancer referral, she may ask whether the pill "caused" this. The honest answer: OCP is a small contributor to breast cancer risk, but the pill does not "cause" a specific cancer presentation. The decision about whether to continue the OCP should be patient-led and discussed after the referral result is known. For now: do not create additional guilt about OCP use. If breast cancer is confirmed, hormonal contraception should be stopped whatever the receptor status, unless the breast/contraception specialist advises otherwise — offer a non-hormonal method.
"I know you might be wondering whether the pill is connected to this. The pill does have a small association with breast cancer risk — but it doesn't cause a specific lump. We don't need to make any decisions about your contraception today — let's get the test results first, and then we can discuss everything."📊 Statistics and Prognosis Anxiety
Sarah has been Googling. She may have encountered survival statistics, stage-specific mortality data, or stories of young women with breast cancer. The GP should acknowledge that statistics were probably encountered without asking what she found — this validates the experience without amplifying it. The honest message: "most breast lumps turn out to be benign; the tests will tell us which category you fall into; and if this is cancer, being seen early is the best possible position to be in." This is accurate, hopeful, and not falsely reassuring.
"I imagine you've been reading things online — most people do. I want to put the statistics in context: most breast lumps are not cancer, and even among those that are, being seen early makes a very significant difference to outcomes. I am not going to tell you this is definitely benign — but I am going to tell you that the fact you came in now, and that we are getting you to a specialist quickly, puts you in the best possible position."- Falsely reassuring ("I'm sure it's nothing") — undermines trust if result is abnormal; also clinically inaccurate
- Delaying referral to "watch and wait" — NICE NG12: suspected cancer pathway referral for unexplained lump in ≥30 years, regardless of clinical assessment
- Not addressing the 6-week concealment and family not informed — the psychosocial context is as important as the clinical characterisation
Same Day / <2 Weeks
Same-day or urgent suspected cancer pathway referral- Suspected inflammatory breast cancerRapid breast swelling + skin erythema + warmth + peau d'orange → urgent breast assessment; escalate if not improving promptly with appropriate treatment; do not delay
- Signs of distant metastasis at presentationBone pain + weight loss + hepatomegaly + neurological symptoms → urgent staging bloods; priority suspected cancer pathway referral; consider CT
- Skin changes suggesting cancer (peau d'orange, dimpling)Consider suspected cancer pathway referral (NG12 1.4.2), any age; may represent locally advanced disease
Urgent Suspected Cancer Pathway
Refer within 2 working days of GP decision- Unexplained breast lump aged ≥30 — SarahSuspected cancer pathway referral: breast-clinic assessment (clinical exam + imaging + biopsy if indicated)
- Bloodstained nipple discharge — under 50 (clinical judgement; NG12 criterion is ≥50)Urgent breast clinic: ductoscopy ± duct excision; cytology of discharge
- Nipple changes aged ≥50 yearsSuspected cancer pathway referral: new retraction, ulceration, eczematous nipple change (Paget's disease)
- Unexplained axillary lump aged ≥30Suspected cancer pathway referral: breast examination; USS axilla; exclude occult primary
Non-urgent referral or GP management
No suspected cancer pathway referral criteria- Cyclical mastalgia without lump (any age)Reassurance; supportive bra; topical NSAID if required (evening primrose oil not routinely recommended); refer if persistent or severe
- Galactorrhoea (milky bilateral discharge)Prolactin; TFTs; review medications (metoclopramide, domperidone, antipsychotics); not a suspected cancer pathway referral unless lump present
- Saying "I don't think this is cancer so we'll monitor it for 6 weeks" — dangerous delay; not NICE NG12-compliant; represents a significant clinical error in a 47-year-old with a 6-week unexplained lump
- Not documenting chaperone offer — GMC standard; regardless of outcome, the offer must be documented
- Examining only the symptomatic breast — both breasts, axillae, and supraclavicular fossae must be examined; unilateral examination is an incomplete clinical examination
- Independently ordering a mammogram or USS from GP — this delays the suspected cancer pathway and fragments the triple assessment process; the mammogram needs to happen alongside specialist examination
"I am referring you to the breast specialist clinic on what is called a suspected cancer pathway. The reason I am doing this is not because I think this is cancer — I do not know what this is. What I do know is that any unexplained breast lump needs to be properly assessed with tests that I cannot do here in the GP surgery. At the clinic you will have an examination by a specialist, an ultrasound scan, and a mammogram — and if needed, a small sample taken from the lump with a fine needle or a slightly larger needle under local anaesthetic. Most people who are referred this way are found to have a benign cause — a cyst, a fibroadenoma, or another non-cancerous change. The purpose of doing this quickly is to get you a definitive answer as soon as possible, whichever way it goes."
"I think this is probably a cyst or a fibroadenoma — try not to worry."
"I am going to be honest with you: I cannot tell just from examining it what this is. Even lumps that feel benign to examine need proper testing to be certain. I'm not going to guess — I'm going to make sure you get the tests that give you a definite answer."
"Come back in a month and we'll see if it has changed."
"Waiting is not the right approach here. The guidelines say that any unexplained lump like yours needs to be assessed urgently — not because it is necessarily serious, but because the tests need to be done now, not later. Waiting adds to your anxiety without giving you any information."
DCIS — Stage 0
Ductal carcinoma in situ: non-invasive; ductal microcalcifications on mammogram; excellent prognosis; surgery ± radiotherapy ± endocrine therapy.
B3/B4 Uncertain/Suspicious
Atypical ductal hyperplasia; lobular neoplasia; radial scar — all require excision biopsy for definitive diagnosis.
Invasive ductal carcinoma (IDC)
Most common (~80%); hard, irregular, spiculated on imaging; graded 1–3; receptor status (ER/PR/HER2) drives treatment.
Invasive lobular carcinoma (ILC)
~15%; diffuse growth pattern; harder to detect; bilateral risk; ER+/HER2- typical; may be larger at diagnosis.
Inflammatory breast cancer
Rare; aggressive; peau d'orange; rapid onset; usually metastatic at diagnosis; urgent; chemotherapy first then surgery.
- Giving false reassurance ("it feels benign — don't worry") before triple assessment is complete — undermines trust; inaccurate; not guideline-compliant
- Not explaining what happens after the referral — Sarah needs to know what to expect and what to do if she does not hear
- Not offering to see Sarah again before or after the clinic appointment — a 47-year-old woman with a potential cancer diagnosis, who hasn't told her family, may need a pre-clinic or post-result GP appointment
Validate the need for reassurance
Sarah wants to be told it is nothing. This is a completely understandable and legitimate need. The GP should validate this need, not dismiss it: "I understand you would love me to tell you this is nothing. I can't do that yet — but what I can do is make sure you get the tests that will tell us for certain."
"I completely understand that what you came in hoping for was for me to say 'it's nothing, go home.' I wish I could say that confidently. But the honest thing to do is to make sure we get the tests that give you a definite answer — either way."Explain what the suspected cancer pathway referral gives her that monitoring doesn't
The suspected cancer pathway referral gives Sarah an answer within 28 days. "Watching and waiting" gives her 6 more weeks of anxiety without a diagnosis. Framing the referral as a gift of certainty — not a confirmation of cancer — converts the referral news from threatening to helpful.
"The urgent referral means you should be seen quickly and get an answer within 4 weeks (28 days). If we just monitor it, you'll still be sitting with this uncertainty in 6 weeks' time — and you've already had 6 weeks of that. The referral is the fastest way to know, whichever way it goes."Offer something concrete today
Even though the diagnosis must wait for the breast clinic, there are things the GP can give Sarah today: an explanation of what will happen at the clinic; the Breast Cancer Now helpline number; an offer to see her before or after the clinic appointment; and the explicit statement that she has done the right thing by coming in now.
"Here is what I want to give you today: an urgent referral to the specialist clinic; a helpline number in case you want to talk to someone before your appointment; and an offer to see you again before or after the clinic. You don't have to navigate this alone."Alcohol increases breast cancer risk by approximately 7–10% per 10g alcohol/day. Mechanism: alcohol increases circulating oestrogen and IGF-1; reduces folate (anti-proliferative). 15 units/week = above safe limits (14/week). Even modest alcohol reduction is associated with meaningful cancer risk reduction. For women with alcohol-related breast cancer, abstinence or near-abstinence reduces recurrence risk.
Brief intervention (FRAMES approach); "I want to mention that alcohol does have a small association with breast cancer risk. Getting it below 14 units a week is worth considering. I am not saying this to add to what you are dealing with today — just so you have all the information."
Regular physical exercise reduces breast cancer risk by approximately 20–30% (both pre and post-diagnosis). Mechanism: reduces adipose tissue (oestrogen source), reduces insulin/IGF-1, improves immune surveillance. Post-diagnosis: exercise significantly reduces recurrence risk and mortality in ER+ breast cancer. Meta-analyses show post-diagnosis exercise reduces all-cause mortality by ~34% and breast cancer-specific mortality by ~41%.
At least 150 minutes moderate exercise (brisk walking, cycling, swimming) per week. Resistance training: additional benefit for bone health (important during aromatase inhibitor therapy). Start before treatment if possible; continue through treatment as tolerated.
Obesity (BMI >30): increased breast cancer risk post-menopause because adipose tissue becomes primary oestrogen source after menopause (aromatase converts androgens to oestrogen). Pre-menopausal obesity: paradoxically slightly lower ER+ risk but higher ER- risk. Post-menopausal weight gain increases ER+ breast cancer risk significantly. Weight loss if obese: reduces breast cancer risk and recurrence risk.
Sarah: 47, pre-menopausal; BMI status not provided; emphasise maintaining healthy weight as she approaches menopause. If treatment involves aromatase inhibitors (post-menopausal or ovarian suppression): weight management particularly important.
Sarah breastfed for 6 months: modest protective effect. Each 12 months of cumulative breastfeeding: approximately 4% reduction in breast cancer risk. Mechanism: prolonged amenorrhoea (reduced cumulative oestrogen exposure); differentiation of mammary gland cells (reducing cancer-susceptible stem cells). Acknowledge as a positive: "breastfeeding is one of the factors that is protective — you've already done that."
If Sarah is pre-menopausal and breast cancer is confirmed: discuss pregnancy after treatment (generally safe 2–3 years after treatment completion for ER+ disease; egg preservation before chemotherapy if applicable).
NHS Breast Screening Programme: 3-yearly mammography 50–71. Invitation-based. Sarah: 47 — not yet in screening age range; should be registered and invited at 50. Women over 71 can request screening; symptomatic women under 50 are referred via the breast pathway, not directed to screening. Familial risk: enhanced surveillance arranged by the specialist service according to calculated risk (not a universal MRI-from-30 rule). NHS programme prevents approximately 1,300 deaths/year in England.
Breast awareness (not self-examination): know what is normal for you; report changes promptly. "Any new lump, skin change, nipple change, or axillary swelling — report immediately, not after 6 weeks." Remove stigma about seeking review for breast symptoms.
NICE CG164: offer chemoprevention to women at high risk of breast cancer (lifetime risk ≥30%, including BRCA1/2 carriers) and consider it for women at moderate risk (lifetime risk 17–30%); risk is estimated in secondary care (e.g. Tyrer-Cuzick model). Tamoxifen (20mg OD × 5 years): pre-menopausal; reduces risk ~38%; DVT/PE, endometrial cancer risk. Anastrozole (1mg OD × 5 years): post-menopausal or post-oophorectomy; reduces risk ~50%; bone loss — use with bone density monitoring.
Sarah: not currently meeting chemoprevention criteria (low-moderate risk from family history + alcohol; no confirmed BRCA mutation; no atypical histology). If triple assessment shows atypical hyperplasia (B3): reassess chemoprevention eligibility. If BRCA confirmed: tamoxifen discussion.
- Tamoxifen 20mg OD: pre/perimenopausal ER+ cancer; 5–10 years; reduces recurrence by ~50%; GP monitors: unexpected vaginal bleeding (prompt urgent gynaecology assessment), DVT/PE risk, mood; STOP OCP (hormonal contraception avoided in current breast cancer; offer a non-hormonal method)
- Aromatase inhibitors (anastrozole, letrozole, exemestane): post-menopausal (or with ovarian suppression); 5–10 years; reduces recurrence by ~55%; GP monitors: bone density (DEXA at start; bisphosphonate if osteoporotic); joint pain (common side effect — "aches and pains"); menopausal symptoms management
- Ovarian suppression: GnRH agonist (goserelin/leuprorelin) in pre-menopausal high-risk ER+ — GP may continue injections prescribed by oncology
- Trastuzumab (Herceptin): HER2+ disease; 12 months IV infusion; cardiac toxicity risk; LVEF monitoring (echocardiogram at baseline, 3-monthly, 12-month); GP monitors: cardiac symptoms; do NOT give with anthracyclines simultaneously (cardiotoxic)
- Pertuzumab (Perjeta): neoadjuvant/adjuvant with trastuzumab in high-risk HER2+ disease; GI side effects; diarrhoea management (loperamide)
- Lapatinib: oral; for metastatic or post-trastuzumab disease; hepatotoxicity monitoring; diarrhoea; rash
- Febrile neutropenia: febrile, rigoring, acutely unwell or any temperature abnormality during chemotherapy → acute oncology emergency pathway immediately (do not rely on 38°C alone); prophylactic G-CSF in high-risk regimens; temp chart patient education
- Nausea: ondansetron; metoclopramide; dexamethasone (chemotherapy anti-emetic protocol)
- Peripheral neuropathy: taxane-related; report to oncologist; consider dose reduction
- Premature menopause: ovarian failure from alkylating agents; HRT usually contraindicated (ER+ disease); non-hormonal options: venlafaxine for hot flushes; vaginal oestrogen (topical only — controversial in ER+; oncologist decision)
- Wide local excision (WLE) + radiotherapy: equivalent survival to mastectomy for most Stage I–II cancers; preferred when feasible
- Mastectomy indications: multifocal disease; large tumour relative to breast size; BRCA mutation (increased contralateral risk); patient preference; previous radiotherapy
- Sentinel lymph node biopsy (SLNB): standard of care for clinically node-negative disease; avoids full axillary clearance; reduces lymphoedema risk
- Breast reconstruction: immediate or delayed; GP counselling on body image and recovery
- Annual mammography (surveillance imaging): years 1–5 after WLE; breast clinic arranges
- Tamoxifen monitoring: per oncology care plan (LFTs only if the plan requires); unexpected vaginal bleeding; DVT/PE symptoms; mood
- Aromatase inhibitor monitoring: fracture risk and bone density per oncology/local bone-health guidance; bone protection per BMD and fracture risk; joint pain management
- Cardiac monitoring if trastuzumab: LVEF at baseline and 3-monthly during treatment
- Bone health on aromatase inhibitor: calcium + vitamin D according to status (not automatic); weight-bearing exercise
- Recurrence symptoms to act on: new bone pain; new lump; contralateral axillary nodes; respiratory; neurological
- ER+/PR+ disease (hormone receptor positive)
- HER2+ disease
- Triple negative (ER-/PR-/HER2-)
- Pre-menopausal
- High familial risk (BRCA)
- Metastatic disease
"Tamoxifen works by blocking oestrogen receptors in breast tissue — it's one of the most effective treatments for your type of breast cancer. Most people tolerate it well. The most common side effects are hot flushes and occasionally mood changes. The important things to watch for are: any unusual bleeding from the vagina — tell us the same day; any pain or swelling in one leg; or any chest pain or breathlessness. Take it at the same time every day — it doesn't matter whether with food or not, but with food helps if it causes any nausea."
Tamoxifen: OCP CONTRAINDICATED in current breast cancer (any receptor status unless specialist-advised) — stop OCP on diagnosis; discuss non-hormonal contraception. Paroxetine and fluoxetine: reduce tamoxifen efficacy (CYP2D6) — use sertraline or venlafaxine instead. Endometrial cancer risk: abnormal uterine bleeding → urgent referral. DVT/PE risk: counsel on symptoms; mobilisation; consider LMWH for high-risk periods (long flights, immobility).
"This tablet works by blocking the last source of oestrogen in your body after the menopause — it's very effective at stopping the cancer from coming back. The main side effect to know about is joint and muscle aches — this affects around half of people on it. If the aches become intolerable, tell us, because we can switch to a different tablet in the same family. The other important thing: it reduces the calcium in your bones, so I'm going to arrange a bone scan and we'll check whether you need calcium and vitamin D tablets."
Aromatase inhibitors: POST-MENOPAUSAL ONLY; confirm menopausal status; do not prescribe to premenopausal women without ovarian suppression. Joint pain: most common cause of non-compliance — manage; switch AI type if severe; non-compliance doubles recurrence risk. DEXA and bone protection per BMD, fracture risk and local guidance; calcium + vitamin D according to status. Greater efficacy than tamoxifen in post-menopausal disease.
"This treatment targets a specific protein on your cancer cells called HER2. It's given as a drip or injection once every 3 weeks for a year. It's very effective for this type of cancer. The main thing we monitor is your heart function — we do a heart scan before you start and every 3 months during treatment. If you develop any breathlessness, swelling in your ankles, or palpitations, tell us promptly. Also important: do not get pregnant during treatment or for 7 months after finishing — we'll discuss contraception."
Trastuzumab: HER2+ disease; LVEF monitoring mandatory (echo baseline, 3-monthly, 12-month end of treatment); LVEF drop to <50% or ≥10 point drop = withhold + cardiology. NOT concurrently with anthracyclines. Pregnancy CONTRAINDICATED. Breast cancer counselling: stop hormonal contraception once breast cancer confirmed; non-hormonal contraception (essential with trastuzumab); pregnancy test before treatment. GP role: cardiac symptom monitoring; drug interaction alert.
"The most important thing for you to know during chemotherapy: if your temperature is 37.5°C or higher, or if you feel unwell, shivery, or generally not right — do not wait to see if it passes. Go to A&E or call the oncology helpline immediately, at any time of day or night. This is because chemotherapy temporarily reduces your white blood cells, and a temperature during this time can become a serious infection very quickly. We'll give you a card with the numbers."
Febrile neutropenia: febrile, rigoring, unwell or any temperature abnormality during chemotherapy = acute oncology emergency pathway immediately (do not rely on 38°C alone); GP gives written guidance card; IV antibiotics within 1 hour of presentation. Fertility preservation: refer to fertility services BEFORE chemotherapy if patient of childbearing age — premature menopause risk from alkylating agents. Stop hormonal contraception once breast cancer confirmed; non-hormonal contraception during chemotherapy. Peripheral neuropathy (taxanes): dose reduction if Grade 3; report to oncologist.
"This tablet exploits a specific weakness in your type of cancer — the same mutation that increases your risk is what makes the cancer respond to this drug. You take it twice a day for a year after your chemotherapy. The main side effects are nausea and fatigue, and we'll check your blood count monthly because it can occasionally affect the blood. The most important message: effective contraception is absolutely essential — pregnancy is not safe during this treatment or for 6 months afterwards."
Olaparib: PARP inhibitor; BRCA1/2 germline mutation + HER2- early high-risk breast cancer; 1 year post-chemotherapy; NICE TA886 (2023; OlympiA trial). Monthly FBC: anaemia, neutropenia, MDS screening. Pregnancy CONTRAINDICATED: effective contraception mandatory. BRCA family cascade: first-degree relatives of confirmed BRCA carriers should be offered genetic counselling and testing. Drug interactions: CYP3A4 inhibitors — dose reduction needed.
"The hormone tablets you're taking for your breast cancer reduce oestrogen levels, which is important for preventing the cancer coming back — but it also reduces the calcium that normally stays in your bones. I'm going to arrange a bone scan to check your bone density. In the meantime, I'll check whether you need calcium and vitamin D tablets. If the bone scan shows your bones have become thinner, we'll add another tablet or injection to protect them. The other important thing: let your dentist know you're on this medication, and get a dental check before we start any bone-protecting injection."
Aromatase inhibitor + bone protection: calcium + vitamin D according to status; DEXA at baseline; bisphosphonate (alendronate) or denosumab if T-score <-2.0. Dental review before bisphosphonate/denosumab (ONJ prevention). Alendronate: renal function check (contraindicated if GFR <35); correct technique mandatory (full glass water; 30 min upright). Denosumab: calcium before each dose (hypocalcaemia risk). GP role in breast cancer: bone health is a core GP responsibility.
The Waiting Period
The wait between referral and the breast clinic result is often described by patients as the most stressful period of their life — worse, for some, than the diagnosis itself. Uncertainty is harder to tolerate than most bad news. The GP can reduce this suffering by setting expectations clearly: what will happen at the clinic, approximately when results will be known, and how results will be communicated.
"The imaging results are often available the same day at the clinic. The biopsy result usually takes 1–2 weeks. You'll be told by the breast specialist or breast nurse. If you haven't heard by the date they give you, you have every right to call them."Disclosure — Who to Tell
Sarah has not told her husband or family. The GP should not pressure her to disclose before she is ready — disclosure is her choice and her timing. However, the GP can gently explore the practical question: "Is there someone who could come with you to the clinic?" A person who attends a potential cancer diagnosis appointment alone is at significantly higher risk of distress and poor information retention. The question is both practical and supportive.
"You don't have to tell anyone anything today. But you're going to have an appointment soon where there might be quite a lot of information — it's a lot easier to process if there's someone with you. You don't have to tell them everything now — just enough for them to come along."Career and School
Teaching is a physical and emotionally demanding role. A breast cancer diagnosis with treatment will have significant occupational implications: surgery requires 2–4 weeks recovery; chemotherapy involves fatigue and infection risk across a school term. Early discussion of sick leave, occupational health, and workplace disclosure (when and how) is important. Macmillan Cancer Support has a dedicated Work and Cancer service.
"I know you're mid-term and the timing of this is dreadful. Whatever the results, there is support available — there are services specifically designed to help people manage their job alongside a cancer diagnosis. You should not feel pressure to continue working through treatment if that's what it comes to."Online Searching and Information Overload
Sarah has been Googling for 6 weeks. She has almost certainly encountered worst-case scenarios, survival statistics, and stories that may not reflect her own situation. The GP should acknowledge this directly without shaming: "I imagine you've been reading things online." Redirecting to reliable information sources (Breast Cancer Now; Cancer Research UK; NHS.uk) reduces exposure to unreliable or distressing information.
"I imagine you've spent a lot of time reading things online. The best sources are Breast Cancer Now — they have a helpline (number on their website) — and Cancer Research UK. The information there is reviewed by medical experts and is accurate. Please try to avoid reading individual stories or statistics that don't relate to your specific situation."Today — Suspected Cancer Pathway Referral Appointment
Suspected cancer pathway referral sent same day. Examination documented (lump characteristics; lymph nodes; skin; nipple). Chaperone documented. Family history documented (3-generation pedigree; BRCA criteria assessed). Breast Cancer Now helpline signposted (number on their website). Offer pre-clinic appointment. Prepare Sarah for breast clinic (examination + imaging + possible biopsy). OCP: continue for now; review after diagnosis. Alcohol brief intervention.
1–2 Weeks — Pre-Clinic or Post-Clinic GP Appointment
Offer to see Sarah before or after the breast clinic appointment. If before: address ongoing anxiety; ensure someone is accompanying her. If after: results discussion; emotional support; next steps planning; family disclosure support if needed. If benign result: full reassurance; breast awareness advice; return criteria. If malignant result: GP role in supporting oncology pathway; medication adjustments (stop hormonal contraception); sick notes; family support.
Post-Diagnosis — MDT Support and Treatment
If cancer confirmed: stop OCP (any receptor status unless specialist-advised); non-hormonal contraception; fertility preservation discussion if pre-menopausal and chemotherapy planned; sick note; occupational health referral; psychosocial support (Macmillan; Breast Cancer Now). GP continues monitoring throughout treatment: side effects; cardiac function (trastuzumab); bone health (AI therapy); mood (PHQ-9); febrile neutropenia awareness.
Annual Surveillance Review
Annually after breast cancer treatment: PHQ-9 (depression common post-treatment); bone density (DEXA if on AI); tamoxifen monitoring (unexpected vaginal bleeding; DVT/PE; LFTs only if the oncology plan requires; mood); aromatase inhibitor monitoring (joint pain; DEXA; bisphosphonate); mammography surveillance (annual × 5 years — breast clinic arranges); recurrence symptoms screening (new bone pain; weight loss; new lumps; respiratory). BRCA cascade testing offered to first-degree relatives.
GP monitoring in breast cancer care
At suspected cancer pathway referral (today): document examination; chaperone; family history; BRCA criteria; psychological support offered. Post-diagnosis: stop OCP (any receptor status unless specialist-advised); non-hormonal contraception; fertility discussion if pre-menopausal + chemotherapy. Tamoxifen: LFTs only if the oncology plan requires; unexpected vaginal bleeding → urgent gynaecology assessment; DVT/PE symptoms; mood (PHQ-9); drug interactions (avoid paroxetine/fluoxetine). Aromatase inhibitors: bone density per oncology/local guidance; calcium + vitamin D according to status; bone protection per BMD and fracture risk; joint pain management; compliance (50% non-compliance at 5 years — review at every consultation). Trastuzumab: LVEF echo baseline + 3-monthly; cardiac symptoms. Chemotherapy: febrile neutropenia awareness (febrile, rigoring, unwell or any temperature abnormality → acute oncology pathway immediately); FBC; nausea management; fertility preservation pre-treatment. Olaparib: monthly FBC (anaemia, MDS). Denosumab/bisphosphonate: dental review; renal function; calcium before each denosumab dose.
⚠ Three essential safety-net conversations in breast cancer management
Documentation requirements — suspected cancer pathway referral consultation
- False reassurance ("I'm sure it's nothing") — undermines trust; clinically inaccurate; may cause patient to cancel clinic appointment
- Watchful waiting without suspected cancer pathway referral — not NICE NG12-compliant; dangerous for a 47-year-old with a 6-week unexplained lump
- Not addressing the family not told — a significant psychosocial factor that affects Sarah's ability to cope with the referral period
- Not offering helpline or follow-up appointment — abandons patient in the most psychologically difficult waiting period
- Chaperone not documented — GMC standard violation
- Suspected cancer pathway referral decision explained correctly (symptom-based, not probability-based)
- Clinical examination documented with chaperone
- Family history 3-generation pedigree; BRCA criteria assessed
- Risk factors contextualised: OCP, alcohol, breastfeeding history
- Triple assessment explained; breast clinic preparation
- Helpline given; follow-up offered; OCP plan discussed
- Fear acknowledged before clinical history
- ICE all three; friend's cancer experience acknowledged
- Suspected cancer pathway referral framed as certainty, not confirmation of cancer
- Family not told — acknowledged without pressure; support offered
- False reassurance avoided; honest about uncertainty
- Helpline and follow-up offered; not left alone
Who you are
Sarah Hughes, 47, secondary school English teacher at a local state school in south London. Married to David, 49 (accountant). One child, Jamie, 19, at university. You found the lump 6 weeks ago while in the shower. You told yourself it was probably a cyst and tried to ignore it. Your close friend Nicola was diagnosed with breast cancer 3 years ago aged 44 — she had a mastectomy and chemotherapy; she is now well. You have not told David or Jamie because you don't want to worry them "if it's nothing." You have been googling "breast lump symptoms" late at night after David has gone to sleep. You have read about fibroadenomas and also about triple negative breast cancer. You are frightened but trying to seem calm. You are on Microgynon (combined OCP) for contraception. You do not smoke. You drink approximately 2 large glasses of wine nightly (roughly 15 units/week). You breastfed Jamie for 6 months. Mother diagnosed with breast cancer age 63 (had lumpectomy and radiotherapy; doing well). No other family members with breast cancer. Periods are regular. BMI approximately 23. You are fit and healthy otherwise.
Hidden concerns — reveal only if ICE explored
What you really fear: You are terrified it is cancer. Specifically, you are scared of losing your breast (body image), of chemotherapy (you watched Nicola lose her hair and be exhausted), and of dying before Jamie finishes university. You will not volunteer these fears unless asked what specifically worries you.
Google searching: You have spent many late nights reading. You know that triple negative breast cancer has a worse prognosis. You have also read that most lumps are benign. You are oscillating between these two framings. If asked what you have been reading, you will admit it and will feel somewhat embarrassed.
Why you haven't told David: You have tried to protect David from worry before (you minimised your anxiety levels for years). You also think that if you don't say it out loud, it might not be real. If asked directly and kindly, you will say this. You will be emotional.
The OCP: You will ask whether the pill could have caused this. You need a clear, non-blaming answer.
The delay: You are aware you should have come sooner. You feel guilty about the 6-week delay. If the GP is judgmental about this, you will feel worse. If the GP is matter-of-fact and reassuring ("coming in now is what matters"), you will feel a significant reduction in guilt.
Clinical details if asked directly
- Lump location: right breast, upper outer quadrant (you show the GP where it is)
- Duration: first noticed 6 weeks ago; has it changed? "I think it might be a tiny bit bigger — I'm not sure"
- Consistency: feels firm, not soft, not painful when you press it
- Nipple: no discharge, no change in nipple that you have noticed
- Skin: no skin changes that you have noticed
- Axilla: no lump under your arm that you have noticed
- Systemic: no weight loss, no bone pain, no breathlessness, no fatigue beyond normal work stress
- Menstrual: regular periods, last period 2 weeks ago, no change in cycle
- Family history: mother breast cancer age 63 (lumpectomy + radiotherapy; well); no other affected relatives on either side that you know of
Reactions at key moments
- On suspected cancer pathway referral: "So does that mean you think it's cancer?" → responds well to clear, calm explanation that suspected cancer pathway referral is for all breast lumps, not a signal of malignancy; will calm down if framed as "fastest route to an answer"
- On chaperone offer: "Yes, that's fine" — cooperative; no objection
- On false reassurance attempt: if GP says "I think it's fine, probably a cyst" → Sarah initially relieved → then: "but you said you couldn't be sure — how do you know?" → distrust develops; may cancel clinic appointment
- On helpline: "I didn't know that existed — that's actually really helpful. Can I write that down?"
- On family not told: if asked kindly — becomes emotional: "I just didn't want to frighten David until I knew something. He worries about me. I don't want to be a burden." → needs acknowledgement not advice
- On OCP: "Could the pill have caused this?" → needs non-blaming accurate answer
- Challenge line: "You seem very calm — is that because you think it's nothing? Just tell me honestly what you really think."
Resolution: Sarah will accept the consultation as satisfactory if the GP: (1) acknowledges her fear before the clinical history; (2) makes and clearly explains the suspected cancer pathway referral without false reassurance; (3) acknowledges Nicola's cancer without catastrophising; (4) addresses the family not told with empathy and practical support (helpline; offer to accompany); (5) documents chaperone; (6) assesses BRCA criteria and mentions family history; (7) addresses OCP non-judgmentally; (8) gives Breast Cancer Now helpline number; (9) offers a follow-up appointment; (10) says "you did the right thing coming in today." Sarah will disengage if reassured falsely, if the suspected cancer pathway referral is described as "just in case it's cancer," if the OCP is blamed, or if she is left without practical support for the waiting period.
- Unexplained breast lump ≥30 years: suspected cancer pathway referral
- Skin changes suggesting cancer (any age): consider suspected cancer pathway referral (NG12 1.4.2)
- Unexplained axillary lump ≥30 years: suspected cancer pathway referral
- Nipple changes ≥50 years: suspected cancer pathway referral
- Bloodstained nipple discharge any age: suspected cancer pathway referral
- Inflammatory signs not improving promptly on appropriate treatment: urgent breast assessment (not an NG12 criterion)
- Signs of distant metastasis: priority suspected cancer pathway referral + staging bloods
- BRCA criteria met: genetics referral alongside suspected cancer pathway referral
- Cyclical mastalgia without lump: conservative; reassurance
- Galactorrhoea (bilateral milky): prolactin; TFTs; medication review